For drugs in moderately rare conditions with competitive pressure from structurally distinct molecules, the practical barrier may be weaker than the statutory term suggests
The response to linsitinib is inferior to the topoisomerase inhibitor topotecan, with median progression-free survival of 3.0 (95% CI 1.53.6) and 1.2 (95% CI 1.11.4) months for topotecan and linsitinib, respectively [159]
For a small, water-soluble copper peptide, absorption from that depot would be expected to be reasonably efficient, but the depot also gives local peptidases and the local copper environment a first opportunity to act on the molecule before it reaches the systemic circulation
Follow the instructions in the Showering section
The international team of researchers behind the new study wanted to see whether genetics may be playing a part
Vomiting and diarrhoea these symptoms usually diminish over time but can be troublesome initially